Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

NCT01529749 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: EFV/FTC/TDF + Losartan
DRUG: EFV/FTC/TDF
DRUG: FTC/TDF + MK-0518
DRUG: FTC/TDF+MK-0518+Losartan

Sponsor

Felipe Garcia